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Summary
Background The coverage of mass drug administration (MDA) for neglected tropical diseases, such as the soil-transmitted 
helminths (STHs), needs to rapidly expand to meet WHO’s 2020 targets. We aimed to compare use of a cost function to 
take into account economies of scale to the standard method of assuming a constant cost per treatment when investigating 
the cost and cost-eﬀ ectiveness of scaling up a STH MDA programme targeting Ascaris lumbricoides. 
Methods We ﬁ tted a cost function describing how the costs of MDA change with scale to empirical cost data and 
incorporated it into a STH transmission model. Using this cost function, we investigated the consequences of taking 
into account economies of scale on the projected cost-eﬀ ectiveness of STH control, by comparison with the standard 
method of assuming a constant cost per treatment. The cost function was ﬁ tted to economic cost data collected as part 
of a school-based deworming programme in Uganda using maximum likelihood methods. We used the model to 
investigate the total reduction in the overall worm burden, the total number of prevalent infection case-years averted, 
and the total number of heavy infection case-years averted. For each year, we calculated the eﬀ ectiveness as the diﬀ erence 
between the worm burden or number of cases and the number in absence of treatment. 
Findings When using the cost function, the cost-eﬀ ectiveness of STH control markedly increased as the programme 
was scaled up. By contrast, the standard method (constant cost per treatment) undervalued this and generated 
misleading conclusions. For example, when scaling up control in the projected district from 10% to 75% coverage of 
at-risk school-age children, the cost-eﬀ ectiveness in terms of prevention of heavy burden infections was projected to 
increase by over 70% when using the cost function, but decrease by 18% when assuming a constant cost per treatment. 
Interpretation The current exclusion of economies of scale in most economic analyses must be addressed if the most 
cost-eﬀ ective policies for the control of neglected tropical diseases are to be formulated. These ﬁ ndings are also 
relevant to other large-scale disease interventions.
Funding GlaxoSmithKline, Bill & Melinda Gates Foundation, Partnership for Child Development, and Wellcome Trust.
Copyright © Turner et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Mass drug administration (MDA) is used to control 
many neglected tropical diseases (NTDs). This type of 
preventive chemotherapy targets all at-risk eligible 
individuals within deﬁ ned age ranges. Although in 2012, 
700 million people received at least one MDA round, this 
is only 36% of those in need of treatment.1 Since the 
London declaration on NTDs in 2012,2 the availability of 
donated drugs has dramatically increased and is no 
longer regarded as a major bottleneck to the control and 
elimination eﬀ orts of the included NTDs.3 However, the 
scaling up of the implementation of MDA programmes 
remains the key obstacle to reaching the 2020 targets set 
by WHO and the London declaration.2–4 This issue with 
scaling up implementation is particularly true for the 
soil-transmitted helminths (STHs), for which WHO has 
set goals to scale up MDA, so that by 2020, 75% of 
preschool and school-age children in need will be treated 
regularly (ie, annually where prevalence is 20–50% or 
biannually where prevalence exceeds 50%).2,4
MDA programmes have beneﬁ cial economies of 
scale5–8—increasing the number treated reduces the cost 
per treatment (panel). Such economies of scale arise 
because many of the costs associated with MDA are 
ﬁ xed (ie, not dependent on the number treated) and 
therefore increasing the interventions output reduces 
the ﬁ xed cost per treatment (panel). Furthermore, as 
programmes expand they are likely to become more 
eﬃ  cient through better organisation and learning by 
doing.5,12 Such economies of scale are not unique to 
MDA and can also occur for other interventions.13
However, although accounting for economies of scale is 
recommended in economic assessments,14,15 because of 
the absence of detailed cost data, most studies assume 
constant returns to scale12,16–19—ie, the cost per treatment is 
constant, regardless of the number treated. Thus, with 
this assumption, the total cost of MDA would increase 
linearly with the number treated.
In view of this need to rapidly scale up MDA,1–4 
understanding how the cost and cost-eﬀ ectiveness of MDA 
Articles
www.thelancet.com/infection   Vol 16   July 2016 839
programmes might be aﬀ ected by these reported 
economies of scale, and assessment of the potential eﬀ ect 
of ignoring them on policy recommendations, is important.
We aimed to use a STH transmission model to compare 
use of a cost function to take into account economies of 
scale to the standard method of assuming a constant cost 
per treatment when investigating the cost and cost-
eﬀ ectiveness of scaling up a STH MDA programme 
targeting Ascaris lumbricoides. 
Methods
Model
We used a fully age-structured model of the transmission 
dynamics of STHs for this analysis.9,10 In this analysis, we 
used the model parameters pertaining to A lumbricoides 
to act as a case study (appendix).
We used the model to simulate a hypothetical district, 
with a total population of 200 000 individuals at risk of 
infection—chosen to take into account the full range of 
the cost data—and a school-based albendazole treatment 
pro gramme targeting school-age children (5–14 years 
old; about 32% of the total population).9,10 The assumed 
age distribution pertains to sub-Saharan Africa and is 
based on Uganda’s demographic proﬁ le.20 As in previous 
analyses,9,10 three diﬀ erent transmission settings were 
investi gated—low (reproductive number [R0]=2), 
medium (R0=3), and high (R0=5; panel).21 These strati-
ﬁ cations diﬀ er from the WHO prevalence categories for 
reasons described by Truscott and colleagues.9 The 
analysis was done by looking at one district to show the 
key principles clearly, although the conclusions would 
apply to national programmes as a whole.
Within the model, the number treated was varied by 
changing the treatment coverage of the school-age 
children at risk of infection within the district (panel). 
Based on the reported coverages from the districts where 
the cost data were collected,5 a maximum coverage of 95% 
of school-age children was assumed within this analysis—
the upper limit of the reported coverages. MDA does not 
include any previous diagnosis before treatment, so 
uninfected individuals would also be treated.
The eﬃ  cacy of albendazole against A lumbricoides, 
deﬁ ned within the model as the proportion of worms 
expelled per treatment, was assumed to be 95%.22
Costs
We used a cost function that describes how the total cost 
per year of MDA changes with the number treated, g. Two 
terms exist within the function: α1, which represents the 
ﬁ xed costs (ie, those that are incurred, and do not change, 
regardless of how many are treated), and α2, which 
represents the subsequent incremental cost per treatment 
Research in context
Evidence before this study
Mass drug administration (MDA) programmes are used to 
control many neglected tropical diseases (NTDs). Although in 
2012, 700 million people received at least one MDA round, this 
is only 36% of those in need of treatment, and the rate of scale 
up of MDA coverage needs to dramatically increase to achieve 
the 2020 targets set by WHO. Consequently, having a clear 
understanding how the cost and cost-eﬀ ectiveness of MDA 
programmes might change with scale is vital. MDA 
programmes have beneﬁ cial economies of scale—ie, increasing 
the number treated by the programme reduces their cost per 
treatment. Despite widespread understanding of this notion, 
for economic assessments in this specialty to assume constant 
returns to scale is nonetheless common practice—ie, the cost 
per treatment is constant, irrespective of how many are treated. 
We searched PubMed for the terms “economies of scale”, 
“cost-eﬀ ectiveness”, and “mass drug administration”, with no 
date or language restrictions. We identiﬁ ed no studies that 
investigated the implications of using cost functions taking 
into account economies of scale on the cost-eﬀ ectiveness of 
scaling up MDA. When we broadened the search beyond MDA 
interventions, we identiﬁ ed few cost-eﬀ ectiveness studies that 
had included economies of scale, because of the absence of 
data. Therefore, assessment of the likely eﬀ ect of this 
assumption on policy recommendations is essential to 
stimulate informed discussion in this specialty.
Added value of this study
The aim of this analysis was to use a soil-transmitted helminths 
(STHs) transmission model—focusing on Ascaris lumbricoides—
to investigate the eﬀ ect of taking into account versus ignoring 
economies of scale on the costs and cost-eﬀ ectiveness of 
scaling up a STH MDA programme. We investigated two 
assumptions: the commonly used constant cost per treatment 
and use of a cost function ﬁ tted to empirical data on a MDA 
programme, taking into account economies of scale. When 
using this cost function, the projected cost-eﬀ ectiveness of the 
STH control programme markedly increased as it was scaled up 
to treat more people. By contrast, assuming a constant cost per 
treatment (ie, the standard method) undervalued the 
cost-eﬀ ectiveness of scaling up MDA programmes and 
generated some misleading conclusions.
Implications of all the available evidence
The analysis shows the fundamental importance that taking 
into account economies of scale can have in economic 
assessments, and how the common practice of ignoring this 
aspect can have a detrimental eﬀ ect on the conclusions, 
potentially biasing policy. Although this study focused on 
MDA programmes for control of NTDs, the ﬁ ndings are also 
relevant to the assessment of other large-scale control 
interventions that might have economies of scale, such as 
vaccination programmes, vitamin A distribution programmes, 
and malaria control.
See Online for appendix
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(ie, the variable cost). When deriving the cost per treatment 
from the cost function, the ﬁ xed costs, α1, are divided by the 
number treated, g, which consequently decreases the cost 
per treatment with increasing numbers treated, taking into 
account potential economies of scale.
The cost function was ﬁ tted to economic cost data 
collected as part of a school-based deworming pro gramme 
in Uganda. The data were collected across six districts over 
3 years from the perspective of the service provider, since 
the costs of accessing the intervention are likely to be 
negligible.5 The programme cost data were collected 
through semi-structured inter views with district oﬃ  cials 
and by detailed examination of the programme accounting 
records in six intervention districts in Uganda.5 Both 
ﬁ nancial and economic costs were collected; economic 
costs include the opportunity cost of using existing 
Ministry of Health staﬀ  and teachers. The delivery cost 
data are organised into ﬁ ve main cost types: (1) programme 
running costs; (2) community awareness activities; 
(3) training of delivery staﬀ ; (4) drug registration and 
distribution; and (5) production of information, education, 
and com munication material.5 For this analysis, the unit 
cost of albendazole (400 mg) was assumed to be US$0·02 
(2014 prices).23 The ﬁ tting of the cost function to the data 
was done using maximum likelihood methods (appendix).
The diﬀ erent cost components of the intervention 
were identiﬁ ed using an ingredients-based approach, 
taking into account both the number of units and the 
prices of units in the local currency (Ugandan 
Shillings).5 The appendix includes a summary of the 
data. The costs presented in the study by Brooker and 
colleagues5 were adjusted for inﬂ ation using the gross 
domestic product implicit price deﬂ ator and are 
expressed in US$ 2014 prices.24
The cost function taking into account the economies of 
scale was compared with the standard method of assuming a 
constant cost per treatment, b, taken as the mean of the data 
range ($0·85, of which $0·83 is for delivery).5 In this case, the 
total cost per year was derived by multiplying the number 
treated per year, g, by this constant cost per treatment, b. This 
calculation assumes constant returns to scale.
Implementation period and time horizon
WHO recommends that interventions are assessed using 
a 10-year implementation period.14 However, this period 
refers only to the timeframe across which the intervention 
is implemented. The time horizon for the analysis (in 
this case 50 years) is longer to account for the full beneﬁ ts 
of the intervention, which can occur both during and 
after its period of implementation.14
Panel: Glossary
Basic reproductive number (R0)
The mean number of female worm oﬀ spring generated by a 
female worm in the absence of density-dependent or 
mate-availability constraints.
Coverage
The proportion of the targeted population—in this case 
school-age children at risk of infection—that are treated each 
treatment round.
Discounting
The process of adjusting the future values of costs and eﬀ ects to 
show that society prefers to receive beneﬁ ts sooner and pay costs 
later. The discount rate shows the strength of this time reference.
Diseconomies of scale
The increase in the mean cost per unit of output resulting 
from increased production (ie, the opposite to economies of 
scale). This can result from programmes expanding into 
harder-to-reach areas, which can be more expensive.
Economies of scale
The reduction in the mean cost per unit of output resulting 
from increased production. In this case, it refers to the 
reduction in the cost per treatment of an intervention as a 
result of increasing the numbers treated.
Economies of scope
The reduction in the mean cost per unit resulting from 
production of two or more products at once. In this case, it 
refers to the reduction in the cost per treatment when 
delivering more than one intervention at once, such as when 
integrating diﬀ erent control programmes.
Fixed costs
Costs that are not dependent on the quantity of output—ie, in 
this case, costs that are incurred or that do not change 
regardless of the number treated within a district. For example, 
many of the programme running costs at the national level 
would probably be incurred regardless of how many individuals 
are subsequently treated within any given district.
Force of infection
The mean number of incoming worms establishing per person 
per year—a metric for the level of ongoing transmission within 
the model.
Transmission breakpoint
The non-zero parasite density below which a parasite 
population cannot maintain itself and is driven into terminal 
decline and eventual elimination.9–11
Variable costs
Costs that vary in proportion to the quantity of the output—in 
this case costs that are dependent on the number treated. 
A key variable cost is that of the total cost of the drugs 
themselves, which would depend directly on the number of 
treatments given.
Information based on Turner and colleagues.8
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The cost-eﬀ ectiveness ratios (ie, the cost per unit of 
eﬀ ect) were derived by dividing the total cost  accrued 
during the implementation period by the total eﬀ ects 
accumulated across the full time horizon.
These guidelines14 are based on the assessment of 
morbidity control strategies. However, elimination 
strategies, which aim to stop transmission and make 
future control measures unnecessary, might need a 
longer timeframe to account for their long-term 
beneﬁ cial eﬀ ects.25 Therefore, within a subset of our 
simulations, we also considered a longer implementation 
period of 35 years. Our simulation model includes the 
eﬀ ects of sexual reproduction and, as a result, elimination 
is a deterministically deﬁ nable event.21 Elimination has 
been achieved when mean worm burdens have fallen 
below a crucial threshold or, equivalently, the parasite 
burden continues to fall to zero in the absence of 
treatment. As recommended by WHO,14 a discount rate 
of 3% was applied to both the costs and eﬀ ects (panel). 
The sensitivity of the results to both the use of a 0% 
discount rate for eﬀ ects and a rate of 6% for the costs was 
explored, based on WHO-Choice guide lines.14 Because 
the eﬀ ects and costs are still being discounted (panel) at 
3% per year and are only taken into account within the 
50-year time horizon, the projected beneﬁ ts of 
elimination are not inﬁ nite.
Eﬀ ectiveness metrics
The model was used to investigate three diﬀ erent 
eﬀ ectiveness metrics (modiﬁ ed from Medley and 
colleagues26) across the chosen time horizon: (1) the total 
number of worm-years averted (ie, the number of years 
lived with a worm prevented); (2) the total number of 
prevalent infection case-years averted (ie, the number 
of years lived with a prevalent infection prevented); and 
(3) the total number of heavy infection case-years averted 
(ie, the number of years lived with a heavy infection 
prevented). Heavy burden was deﬁ ned as having a worm 
burden above the age-speciﬁ c thresholds for disease 
presented by Chan and colleagues27 (appendix). For 
each year, we calculated the eﬀ ectiveness as the diﬀ erence 
between the worm burden or number of cases and the 
number in absence of treatment (appendix).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
The cost function taking into account the economies of 
scale accounted well for the noted patterns in the cost data 
(ﬁ gure 1). By contrast, the standard method of assuming a 
constant cost per treatment did not correspond well to the 
data; it substantially underestimated the total cost per year 
of treating a small number of individuals and over-
estimated the total cost per year of treating a large number 
of individuals (ﬁ gure 1A).
When using the cost function taking into account the 
economies of scale, the projected cost-eﬀ ectiveness of MDA 
increased substantially as the number of at-risk school-age 
children treated within the district was scaled up. This 
pattern occurred because as treatment was scaled up, the 
increase in cost derived from the cost function (ﬁ gure 1A) 
was smaller than the projected increase in the eﬀ ects 
(ﬁ gure 2A–C). As such, the cost-eﬀ ectiveness ratio (ie, the 
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Figure 1: Estimated cost as a function of the number of at-risk school-age 
children treated within the district, with and without the cost function 
taking into account the economies of scale
Estimated total cost per year (A) and cost per person treated (B) are shown. 
The datapoints show the economic cost of a school-based delivery programme 
in Uganda (including a unit cost of albendazole of US$0·02 per treatment),23 
collected across six districts over 3 years.5 The cost function was ﬁ tted (α₁=9989, 
95% CI 9850–10 117; α₂=0·301, 0·295–0·306) to the total cost per year data (A) 
using maximum likelihood. b was taken as the mean cost from the data ($0·85). 
The costs are in 2014 prices. α₁=ﬁ xed costs (ie, those that are incurred, and do 
not change, irrespective of how many are treated [the intercept in (A)]). 
α₂=incremental cost per treatment (ie, variable costs). b=constant cost per 
treatment. g=number treated. SAC=school-age children.
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cost per eﬀ ect) decreased (ﬁ gure 2D–F). This decrease 
resulted in an increase in the cost-eﬀ ectiveness of control—
scaling up control from 10% to 75% coverage of at-risk 
school-age children within our projected district increased 
the cost-eﬀ ectiveness in terms of preventing heavy 
infections by over 70% (appendix). Because an assumed 
incremental cost per treatment is included within the cost 
function, the gain in cost-eﬀ ectiveness with scale showed 
some diminishing returns and approached a maximum 
level, because the cost per treatment cannot decrease past 
the assumed incremental cost per treatment, α2 (ﬁ gure 1B).
By contrast, when the economies of scale were ignored 
and a constant cost per treatment was assumed—the 
standard method—the projected cost-eﬀ ectiveness 
remained relatively constant when scaling up treatment 
(ﬁ gure 2D–F); it only increased slightly in terms of the 
cost per prevalent case-year averted (ﬁ gure 2E) and even 
decreased in terms of the cost per heavy case-year averted 
(ﬁ gure 2F). Thus, this standard assumption incorrectly 
undervalued the cost-eﬀ ectiveness of scaling up MDA 
because, when assuming the cost per treatment is 
constant, the total cost per year increased linearly with 
the number treated (ﬁ gure 1A). Consequently, when 
scaling up treatment, the increase in both the eﬀ ects 
(ﬁ gure 2) and costs were similar, hence the ratio of the 
two remained constant. The cost-eﬀ ectiveness in terms 
of prevalent case-years and heavy case-years averted 
(ﬁ gure 2E and 3F) changed with scale, because of the 
non-linear gain in eﬀ ects as the coverage of at-risk 
school-age children increased (ﬁ gure 2B and 2C).
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Figure 2: Eﬀ ectiveness and cost-eﬀ ectiveness of school-based mass drug administration
(A–C) Eﬀ ectiveness and (D–F) cost-eﬀ ectiveness of school-based mass drug administration as a function of the number of at-risk SAC treated within the district are 
shown according to eﬀ ectiveness measure (appendix). The number treated was calculated by varying the treatment coverage of SAC at risk of infection within the 
district, with treatment coverage deﬁ ned as the proportion of the targeted population (ie, SAC) receiving treatment. In (D–F) the smaller the cost-eﬀ ectiveness ratio, 
the more cost eﬀ ective mass drug administration is deemed to be. Results assume a 50-year time horizon, a period of implementation of 10 years (ie, ten annual 
treatment rounds), a 3% discount rate, and a total population size of 200 000 individuals, 32% of whom were SAC. SAC=school-age children. 
Worm-years 
averted 
(thousands)
Prevalent case-
years averted 
(thousands)
Heavy case-years 
averted 
(thousands)
Low 6963 201 62
Medium 7889 74 94
High 10 460 38 102
Results assume a 10-year implementation period (ie, up to ten annual treatment 
rounds), a 50-year timeframe, and 75% coverage.
Table: The sensitivity of the total eﬀ ectiveness to the assumed 
transmission setting
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The total eﬀ ectiveness of the intervention in terms of 
the overall reduction in worm burden and the number of 
heavy case-years averted—both metrics that are based on 
infection intensity—increased with the assumed level of 
pre-control endemicity or transmission intensity (table). 
By contrast, the total number of prevalent case-years 
averted—a measure based only on infection prevalence—
decreased as the transmission intensity increased (table). 
This situation arose because of the non-linear relation 
between mean worm burden and prevalence (ﬁ gure 3A), 
created by aggregated distributions of worm numbers (a 
large proportion of worms were in a small proportion of 
individuals); thus, at higher worm burdens, large changes 
in mean worm burden are likely to lead to only small 
changes in prevalence (ﬁ gure 3A). Furthermore, annual 
treatment of school-age children only is not always 
eﬀ ective in terms of reducing the overall level of 
transmission within the population. This ﬁ nding is 
shown by looking at the eﬀ ect of control on the local force 
of infection (panel)—a measure of transmission—which 
decreased as the assumed level of transmission intensity 
was increased (ﬁ gure 3B).
Because of these relations, the higher the transmission 
intensity, the higher the cost-eﬀ ectiveness of the 
intervention in terms of the reduction in the overall 
worm burden and heavy infections averted (ﬁ gure 2D 
and 2F). However, counterintuitively, the cost-eﬀ ective-
ness in terms of the number of prevalent case-years 
averted was higher the lower the level of transmission 
intensity (ﬁ gure 2E). 
The increase in cost-eﬀ ectiveness in terms of heavy 
infections averted as the level of assumed transmission 
intensity was increased shows some diminishing returns 
(table). This ﬁ nding occurred because in high-trans-
mission settings, treatment of school-age children only 
does not eﬀ ectively control the number of heavy 
infections. 
When we included a longer implementation period in 
areas with low transmission intensity (ie, 35 years instead 
of 10 years), the beneﬁ ts of elimination within the 50-year 
time horizon of the analysis became apparent (ﬁ gure 4). 
The potential for local elimination by chemotherapy 
alone is theoretically possible when worm levels become 
low enough for no one individual to harbour both a male 
and female worm, which means eggs are unfertilised 
and transmission is broken—ie, a transmission break-
point (panel). Under these circum stances, the cost-
eﬀ ective ness increased at a faster rate as the coverage 
was scaled up (ﬁ gure 4A). This ﬁ nding occurred because, 
after elimination is achieved, the costs of future control 
are avoided. As coverage is increased, the time to 
elimination is reduced, generating a lower total cost 
(ﬁ gure 4B). When falsely assuming a constant cost per 
treatment—the standard assumption—the total cost of 
scaling up control was overestimated (ﬁ gure 4B). 
Varying the discount rate had little eﬀ ect on the 
projected cost-eﬀ ectiveness of control (appendix) and the 
general conclusions remain unchanged. However, the 
choice of the discount rate for the costs had implications 
regarding the potential cost savings generated by 
reaching elimination (appendix); the higher the discount 
rate, the lower the potential cost savings.
Discussion
Because of economies of scale, the cost per treatment of 
MDA decreased with increasing numbers treated. 
Consequently, projected cost-eﬀ ectiveness of STH 
control programmes markedly increased as they were 
scaled up to treat more at-risk school-age children. 
Although this analysis was done by investigating one 
district targeting primarily A lumbricoides as a case study, 
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these conclusions can be applied more generally to 
national STH programmes. This increase in cost-
eﬀ ectiveness has important impli cations for countries 
and donors that are con sidering scaling up MDA in line 
with the targets set by the WHO and the London 
declaration (appendix).2,4 These results also have 
implications for MDA resource allocation for other NTDs 
that do not have widespread control.
By contrast, the standard method of assuming a constant 
cost per treatment undervalued the cost-eﬀ ective ness of 
scaling up MDA and might even in correctly generate 
misleading conclusions. For example, when scaling up 
control in the projected district from 10% to 75% coverage 
of at-risk school-age children, the cost-eﬀ ectiveness in 
terms of preventing heavy infections was projected to 
increase by over 70% when using the cost function, but 
decrease by 18% when assuming a constant cost per 
treatment (appendix). This analysis shows the funda-
mental importance taking into account economies of scale 
can have in economic assessments, and how ignoring this 
aspect, which is done in most economic assessments, can 
have a detrimental eﬀ ect on con clusions, potentially 
incorrectly aﬀ ecting policy.28 This ﬁ nding is particularly 
relevant to NTDs because of the nature of the costs of 
MDA—many of which are ﬁ xed, because the drugs 
themselves are often donated or inexpensive—but is also 
relevant to other large-scale control programmes.13 
This research generated two other important con-
clusions for resource allocation and programme planning. 
First, accounting for economies of scale when comparing 
the reported costs of diﬀ erent alternative strategies is 
essential, since if ignored analyses might lead to incorrect 
assumptions regarding the relative costs of diﬀ erent 
strategies, and concomitantly might lead to the use of 
suboptimum policies for MDA imple men tation.29 Second, 
use of models that account for the transmission dynamics 
of the parasite under MDA in any economic assessment, 
which can take into account the indirect eﬀ ects of 
interventions, is desirable, as opposed to static models.30
Within this analysis, the potential costs and eﬀ ects of 
expanding the coverage of school-age children beyond 
95% were not considered, because the coverage would 
need to be extrapolated beyond the range of the data used 
to parameterise the cost function.5 In future studies, the 
potential increase in costs and diseconomies of scale 
(panel)13,31,32 will be analysed as programmes are expanded 
to cover harder-to-reach groups (eg, schools in remote 
areas and school-age children who do not attend the 
treatment days). The strength of these diseconomies of 
scale and the point at which they start to apply within a 
control programme will vary in diﬀ erent areas, which is 
likely to have implications regarding the costs to achieve 
elimination and the most cost-eﬀ ective strategy. As such, 
more detailed studies and cost of control measurements 
are needed in these groups.
In the modelled scenarios, elimination with a school-
based strategy was only possible in areas with low 
transmission intensity. To achieve elimination in areas 
with medium-to-high transmission requires an expansion 
of control beyond school-age children to include preschool 
and adults or an increased treatment frequency, or both.9,10 
Although treatment of adults is likely to be more 
expensive initially, it will reduce the duration of 
programme needed, which ultimately is likely to lead to 
cost savings.33
In this analysis, we focused only on A lumbricoides to 
act as a case study. One should note that there remains 
uncertainty surrounding the parameterisation of the key 
epidemiological processes of STH transmission models. 
However, the ﬁ ndings presented regarding the increase 
in cost-eﬀ ectiveness preliminarily arose because of the 
non-linearity in the costs, and therefore these results are 
directly relevant to the other STHs (eg, hookworm and 
trichuris) and parameter estimates. However, elimination 
of hookworm and trichuris would not be possible in 
most settings with only an annual treatment programme 
targeting school-age children, because for hookworm 
most worms are harboured by adults, and for trichuris 
the treatment eﬃ  cacy of albendazole is lower than for 
A lumbricoides.9,10,22 Consequently, treatment of school-age 
children alone does not have as marked an eﬀ ect on 
transmission compared with A lumbricoides.
The presented cost function relates only to a 
programme targeting only school-age children once 
per year. More cost functions were not explored because 
the dataset by Brooker and colleagues5 was the only 
relevant one that could be identiﬁ ed for a STH 
programme.8 These results highlight the need for further 
cost data to be collected so that more comprehensive cost 
functions or predictive costing models can be developed 
to represent a range of diﬀ erent settings, strategies, and 
potential diseconomies of scale.13,31,32 These should be 
able to account for the potential diﬀ erence between 
expansion of control by increasing coverage within a 
district, as shown herein, and expansion to new districts, 
because these are likely to have diﬀ erent economies and 
diseconomies of scale. These cost functions should also 
include potential economies of scope (panel)—ie, how 
integration of diﬀ erent control programmes might yield 
lower costs per treatment.6 The absence of cost data for 
preschool children and adults constitutes a major barrier 
for further research regarding how best to optimise STH 
control and the development of further cost functions for 
the diﬀ erent strategies.
A further need is for the STH specialty to decide which 
are the best eﬀ ectiveness metrics by which to judge 
diﬀ erent control strategies, since this is crucial when 
establishing the choice of intervention.8,34,35 Within this 
debate, consideration of how diﬀ erent programmatic 
objectives might need diﬀ erent eﬀ ectiveness metrics will 
be important. 
This work further shows that when interventions are 
aimed at reducing morbidity, their eﬀ ectiveness metric 
should be based on infection intensity and not simply 
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prevalence. Basing the eﬀ ectiveness metric on prevalence 
in this context can produce counterintuitive and 
misleading conclusions, showing treatment to be more 
cost-eﬀ ective in lower versus higher transmission areas, 
which poorly represents the eﬀ ect of treatment on 
disease burden, which is related to heavy infections. This 
ﬁ nding was also reported by Guyatt and colleagues.34 
The best metric for assessment of the eﬀ ect on 
morbidity within models might be heavy case-years 
averted, which can take into account the fact that a certain 
worm burden can have diﬀ erent health consequences 
depending on the host’s age—just looking at the overall 
reduction in worm burden does not account for this. 
However, the numerical thresholds at which worms 
cause disease are surrounded with uncertainty, and 
probably depend on several host-speciﬁ c factors.35 
Furthermore, translating egg counts—how intensity is 
measured in practice—to number of worms can be 
diﬃ  cult.36 By contrast, when assessing interventions 
aimed at reducing transmission, metrics based on 
morbidity or heavy infections will be misleading, 
undervaluing the potential need to expand treatment to 
other age groups or increase the treatment frequency to 
reduce transmission. 
These results support those of previous modelling 
studies9–11 that showed that when the programmatic aim 
is to reduce transmission, as opposed to morbidity, 
targeting school-age children alone is unlikely to be 
suﬃ  cient to achieve the desired results.9–11,33,37
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